Document
type: Class

individual
rights: termsOfUse
date: 2026-08-24T05:59:39
publisher: Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
type: Document
label: RDF description of Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study - http://irises.uniss.it/resource/item/151846

Academic Article
type: Class

Continuant
type: Class

Entity
type: Class

Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
type: Information Content Entity
type: Entity
type: Document
type: Thing
related by: 11265305
most specific type: Academic Article
type: Article
language: Inglese
type: Continuant
type: Academic Article
type: Generically Dependent Continuant

Generically Dependent Continuant
type: Class

Article
type: Class

11265305
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study

Information Content Entity
type: Class

Inglese
type: Language